| 1 |
35046058 | Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. | 2022 Jan 19 |
8 |
| 2 |
35381683 | [Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report]. | 2022 Feb 14 |
1 |
| 3 |
35443108 | Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. | 2022 Apr 21 |
2 |
| 4 |
35452083 | Shall We Dance: Evolving Partnerships of Targeted Therapies for AML. | 2022 Apr 22 |
1 |
| 5 |
35532213 | Ivosidenib Boosts Azacitidine's Effectiveness in AML. | 2022 May 9 |
1 |
| 6 |
32241846 | Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. | 2021 Feb 1 |
2 |
| 7 |
33043739 | Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. | 2021 Feb |
1 |
| 8 |
33292606 | Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML. | 2020 Nov 25 |
1 |
| 9 |
24077805 | 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. | 2013 Oct |
1 |